

Updated: 05/09/2024

Click on the link below to be directed to study information at "ClinicalTrials.Gov" the US National Institutes of Health website.

| Condition                                |  | Active Research Studies   | St. Luke's Contact   |
|--|--|---|--|
| <u>ANATOMICAL SITE</u>                   | <u>RESEARCH BASE &amp; REFERENCE #</u> | <u>STUDY TITLE</u>  | <u>ST. LUKE'S CONTACT</u>  |
| <u>MDS</u>                               | NHLBI-MDS<br>NCT02775383               | <a href="#">The National Myelodysplastic Syndromes Natural History Study</a>  | Cade M. 218-249-5647<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a> |
| <u>SMOKING CESSATION</u>                 | A211901<br>NCT05008848                 | <a href="#">Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions</a>  | Cade M. 218-249-5647<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a> |
| <u>MULTICANCER EARLY DETECTION</u>       | Alliance<br>A212102<br>NCT05334069     | <a href="#">Blinded Reference Set for Multicancer Early Detection Blood Tests</a>   | Cade M. 218-249-5647<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a> |
| <u>BREAST GASTRIC/ABDOMINAL THORACIC</u> | iCaRe <sup>2</sup>                     | <a href="#">Integrated Cancer Repository for Cancer Research</a>  | Cade M. 218-249-5647<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a> |
| <u>LUNG NSCLC</u>                        | E4512<br>NCT02201992                   | <a href="#">A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein</a> | Cade M. 218-249-5647<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a> |
| <u>LUNG NSCLC</u>                        | Alliance<br>A151216<br>NCT02194738     | <a href="#">Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)</a>  | Cade M. 218-249-5647<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a> |
| <u>LUNG ES-SCLC</u>                      | NRG-LU007<br>NCT04402788               | <a href="#">Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial</a>  | Cade M. 218-249-5647<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a> |
| <u>BREAST PREMENOPAUSAL</u>              | S2010<br>NCT05568472                   | <a href="#">Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study</a>   | Cade M. 218-249-5647<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a> |
| <u>BREAST HER2+</u>                      | NRG-BR008<br>NCT05705401               | <a href="#">Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer (HERO)</a>  | Cade M. 218-249-5647<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a> |
| <u>Breast HER2+</u>                      | Alliance<br>A011801<br>NCT04457596     | <a href="#">T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial</a>   | Cade M. 218-249-5647<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a> |
| <u>Colon Stage II/III BRAF V600E</u>     | Alliance<br>A022004<br>NCT05710406     | <a href="#">Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer</a>   | Cade M. 218-249-5647<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a> |

|   |                            |   |  |
|---|----------------------------|---|--|
| <u>PROSTATE</u>                           | NRG-GU010<br>NCT05050084   | <a href="#">Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score</a>  | Cade M. 218-249-5647<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>   |
| <u>PROSTATE</u>                           | NRG-GU013<br>NCT05946213   | <a href="#">Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer</a>  | Cade M. 218-249-5647<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>   |
| <u>SKIN</u>                               | ECOG EA6174<br>NCT03712605 | <a href="#">Pembrolizumab compared to Standard of Care Observation in Treating Patients with Completely Resected Stage I-III Merkel Cell Cancer</a>   | Cade M. 218-249-5647<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>   |
| <u>PANCREAS</u>                           | EA2192<br>NCT04858334      | <a href="#">APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation</a>   | Cade M. 218-249-5647<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>   |
| <u>UROTHELIAL</u>                         | A032002<br>NCT04936230     | <a href="#">Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)</a>   | Cade M. 218-249-5647<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a>   |
| <u>NSCLC</u>                              | PACIFIC-4<br>NCT03833154   | <a href="#">A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) or Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation</a> | Jessica L. RN,<br>218-249-5581<br>Charity G. RN,<br>218-249-5177<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a> |
| <u>NSCLC</u>                              | PACIFIC-9<br>NCT05221840   | <a href="#">A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab or Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy</a>   | Charity G. RN,<br>218-249-5177<br>Jessica L. RN,<br>218-249-5581<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a> |
| <u>NSCLC</u>                              | AVANZAR<br>NCT05687266     | <a href="#">Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin for First-Line Treatment of Patients With Advanced NSCLC Without Actionable Genomic Alterations vs standard care with pembrolizumab in combination with platinum-based chemotherapy</a>   | Jessica L. RN,<br>218-249-5581<br>Charity G. RN,<br>218-249-5177<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a> |
| <u>LEUKEMIA</u>                           | ReVenG<br>NCT04895436      | <a href="#">Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) (ReVenG)</a>  | Jessica L. RN,<br>218-249-5581<br>Charity G. RN,<br>218-249-5177<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a> |
| <u>SOLID TUMORS WITH BRAF ALTERATIONS</u> | FORE8394<br>MCT02428712    | <a href="#">A phase 2 trial to assess the efficacy and safety of plixorafenib, an inhibitor of BRAF class I and II alterations, in patients with BRAF alterations</a>   | Jessica L. RN,<br>218-249-5581<br>Charity G. RN,<br>218-249-5177<br><a href="mailto:whiteside@slhduluth.com">whiteside@slhduluth.com</a> |